small molecule

NASONEX

MOMETASONE FUROATE

Loss of exclusivity—loss of exclusivity

CompanyOrganon →See this company's full patent-cliff portfolio

Drug detail

Brand name	NASONEX
Active ingredient	MOMETASONE FUROATE
Strength	0.05MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	SPRAY, METERED
Route	NASAL
Modality	Small molecule
FDA approval	October 1997
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.